Bigmar Delisted From the Nasdaq Small Cap Market.Business Editors JOHNSTOWN, Ohio--(BW HealthWire)--Oct. 6, 2000 Bigmar Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :BGMR BGMR Bigmar Inc. (stock symbol) ), a manufacturer of generic pharmaceutical oncology products and intravenous infusion solutions, today announced that it has been notified by the Nasdaq Stock Market Nasdaq stock market The first electronic stock market listing over 5000 companies. The Nasdaq stock market comprises two separate markets, namely the Nasdaq National Market, which trades large, active securities and the Nasdaq Smallcap Market that trades emerging growth companies. Inc. that the company's common stock has been delisted from trading on the Nasdaq Small Cap Market, effective at the close of yesterday's trading. The delisting follows a hearing before the Nasdaq Listing Qualifications Panel. Nasdaq also notified the company that its securities are immediately eligible for trading on the OTC Bulletin Board OTC Bulletin Board An electronic quotation listing of the bid and asked prices of OTC stocks that do not meet the requirements to be listed on the NASDAQ stock-listing system. commencing today, Oct. 6, 2000. Bigmar's strategy is to supply world markets with a line of high-quality, affordably priced pharmaceutical products with a focus on oncology. The company has distribution rights to more than 20 generic oncological products and seven products approved by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. , which are manufactured in the company's state-of-the-art facilities in Switzerland. Bigmar markets its products through partnerships with pharmaceutical distributors in Europe and the United States and focuses on off-patent oncological drugs. For more information, visit the company's Web site, www.bgmr.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion